Creavo enrolls final patient in largest magnetocardiography (MCG) trial of its kind

Trial tests the viability of Creavo’s MCG device at five major emergency departments across the UK.

Creavo Medical Technologies (Creavo), the UK-based medical device company, has completed patient enrollment in its multi-centre study.   Involving 750 patients across five of the UK’s largest emergency departments — Sheffield, Nottingham, Bristol, Leicester and London’s St George’s — the study has been conducted to assess the accuracy of Creavo’s  magnetocardiography (MCG) device in identifying those at low risk of ischaemic heart disease.

Lead investigator Prof Steve Goodacre commented,” The study is entering an exciting phase, in which we will analyse the data to determine the accuracy of the MCG device for aiding the diagnosing of ischaemic heart disease”

The device, which performs a non-invasive scan within minutes at the patient’s bedside, has been designed to aid clinicians meet a clinical need, to quickly rule out ischaemia related heart problems at the point of admission to emergency departments. Identifying these patients early can potentially reduce patient anxiety and can save the hospitals valuable time, resources and bed space. Financially, the device has the potential to save the UK healthcare system up to £200 million a year.

Steve Parker, Chief Executive Officer at Creavo said: “Finalising this important study is a major milestone for Creavo as we work towards our goal of offering rapid diagnostic solutions that improve patient outcomes and meet the needs of healthcare professionals. This study will give us important information and I’d like to thank the experienced healthcare professionals and patients who have supported and participated to make this trial possible.  Feedback from the users has been positive and we’re looking forward to releasing the results in due course.”

There have been a number of notable achievements for Creavo in the last two years.  The device received CE mark registration in Europe in November 2016 and secured 510(k) clearance from the U.S. Food and Drug Administration in October 2017.   Following initial funding, the company raised £13.4m ($17m) in additional private equity funding in July 2017 for its MCG device. The round was oversubscribed and exceeded Creavo’s funding target, reflecting strong investor support and endorsement of the company’s strategy and team.